US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tharimmune Inc.

1.13

-0.0700-5.83%

Volume:4.71K

Turnover:5.49K

Market Cap:2.38M

PE:-0.12

High:1.19

Open:1.19

Low:1.12

Close:1.20

Loading ...

Overview Company News Filings

BRIEF-Tharimmune Inc Announces $2.02 Million Private Placement To Advance Development Programs

Tharimmune Inc: Announces $2.02 Mln Private Placement to Advance Development Programs

THOMSON REUTERS

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

Tharimmune initiated with a Buy at Rodman & Renshaw

DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025

Tharimmune Abandons Acquisition of Intract Pharma

BRIEF-Tharimmune Inc Increases Board Size To Six

Tharimmune Inc - Increases Board Size to Six

THOMSON REUTERS

Tharimmune presents clinical data on TH104 for chronic pruritus

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Tharimmune granted patent for delivery of molecularly targeted therapeutics

Tharimmune: Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

THOMSON REUTERS

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Tharimmune Announces Upcoming Conference Presentations

Tharimmune Shares Climb on Positive Feedback From EMA on Potential Pruritus Therapy

MT Newswires Live

Dow Surges Over 150 Points; Alphabet Posts Upbeat Results

Tharimmune receives regulatory feedback from EMA for TH104 program

Tharimmune - Receives Positive Regulatory Feedback From Ema for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

THOMSON REUTERS

Tharimmune Inc - Expects Topline Data in 2025

THOMSON REUTERS

Tharimmune - Plans to Initiate Phase 2 Multiple-Ascending Dose Trial in Coming Months to Assess Safety and Tolerability of TH104

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/THAR/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"THAR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"THAR\",,,,,undefined,":{"symbol":"THAR","market":"US","secType":"STK","nameCN":"Tharimmune Inc.","latestPrice":1.13,"timestamp":1745342056357,"preClose":1.2,"halted":0,"volume":4713,"delay":0,"floatShares":2077517,"shares":2108753,"eps":-9.409598,"marketStatus":"Trading","change":-0.07,"latestTime":"04-22 14:05:39 EDT","open":1.19,"high":1.19,"low":1.12,"amount":5491.1082879,"amplitude":0.058333,"askPrice":1.18,"askSize":2000,"bidPrice":1.14,"bidSize":213,"shortable":3,"etf":0,"ttmEps":-9.409598,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745352000000},"marketStatusCode":2,"adr":0,"listingDate":1641963600000,"exchange":"NASDAQ","adjPreClose":1.2,"volumeRatio":0.631752},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"THAR\",,,,,undefined,":{"symbol":"THAR","floatShares":2077517,"roa":"-105.96%","roe":"-233.69%","lyrEps":-9.409598,"volumeRatio":0.631752,"shares":2108753,"dividePrice":0,"high":1.19,"amplitude":0.058333,"preClose":1.2,"low":1.12,"week52Low":0.952,"pbRate":"1.82","week52High":6.4485,"institutionHeld":0,"latestPrice":1.13,"committee":-0.807501,"eps":-9.409598,"divideRate":0,"volume":4713,"delay":0,"ttmEps":-9.409598,"open":1.19,"prevYearClose":2.03,"prevWeekClose":1.1299,"prevMonthClose":1.36,"prevQuarterClose":1.36,"fiveDayClose":1.1745,"twentyDayClose":1.53,"sixtyDayClose":2.07},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"THAR\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2489071261","title":"BRIEF-Tharimmune Inc Announces $2.02 Million Private Placement To Advance Development Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2489071261","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489071261?lang=en_us&edition=fundamental","pubTime":"2024-12-07 05:39","pubTimestamp":1733521175,"startTime":"0","endTime":"0","summary":"Dec 6 (Reuters) - Tharimmune Inc   :   * THARIMMUNE INC: ANNOUNCES $2.02 MILLION PRIVATE PLACEMENT TO ADVANCE DEVELOPMENT PROGRAMSSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THAR","BK4139"],"gpt_icon":0},{"id":"2489694042","title":"Tharimmune Inc: Announces $2.02 Mln Private Placement to Advance Development Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2489694042","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489694042?lang=en_us&edition=fundamental","pubTime":"2024-12-07 05:19","pubTimestamp":1733519961,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241206:nFWN3N71S4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","THAR"],"gpt_icon":0},{"id":"2489526152","title":"Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2489526152","media":"ACCESSWIRE","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489526152?lang=en_us&edition=fundamental","pubTime":"2024-12-07 05:15","pubTimestamp":1733519700,"startTime":"0","endTime":"0","summary":"BRIDGEWATER, NJ / ACCESSWIRE / December 6, 2024 / Tharimmune, Inc.  , a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced it has entered into a securities purchase agreement to raise gross proceeds of approximately $2.02 million through a private placement.The agreement includes the issuance of 961,446 shares of common stock  and warrants to purchase up to an additional 480,723 shares of common stock. Each share  is priced at $2.10 and is accompanied by a warrant. The warrants will have an exercise price of $2.031 per share, becoming exercisable six months after issuance and expiring five and one-half years from the date of issuance. The closing of this transaction is expected on or about December 9, 2024, subject to customary closing conditions.The securities in this private placement were offered under Section 4 of the Securities Act of 1933, as amended, and Regulation D thereunder. The shares of common stock and un","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tharimmune-announces-2-02-million-211500097.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PBC","THAR"],"gpt_icon":0},{"id":"2489195234","title":"Tharimmune initiated with a Buy at Rodman & Renshaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2489195234","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489195234?lang=en_us&edition=fundamental","pubTime":"2024-12-06 23:15","pubTimestamp":1733498119,"startTime":"0","endTime":"0","summary":"Rodman & Renshaw analyst Elemer Piros initiated coverage of Tharimmune (THAR) with a Buy rating and $17 price target Published first on TheFly – th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tharimmune-initiated-with-a-buy-at-rodman-renshaw?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tharimmune-initiated-with-a-buy-at-rodman-renshaw?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","THAR"],"gpt_icon":0},{"id":"2486828233","title":"DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2486828233","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486828233?lang=en_us&edition=fundamental","pubTime":"2024-11-27 20:00","pubTimestamp":1732708800,"startTime":"0","endTime":"0","summary":"ATLANTIC CITY, NJ / ACCESSWIRE / November 27, 2024 / DealFlow Events is pleased to announce the initial lineup of companies participating in The Microcap Conference, set for January 28-30 in Atlantic City, NJ. Now in its second year, the event is a key gathering for microcap and small-cap investors, offering a platform for investment and collaboration.Hosted at the Borgata Hotel & Casino, the conference provides executives of public growth companies an opportunity to engage with investors in meaningful discussions. Attendees include seasoned executives, institutional investors, high-net-worth individuals, hedge funds, and others.The event features company presentations, one-on-one meetings, keynote addresses, panel discussions, and networking opportunities. Executive teams from growth companies across sectors such as financial services, healthcare, energy, and technology are confirmed. The conference will host more than 100 companies and 1,500 attendees in the Borgata's main 30,000 sq.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dealflow-events-unveils-first-wave-120000736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QID","FUFUW","SQQQ","ALTS","BK4189","ABLLW","MYPS","IPA","BK4121","EEIQ","BETRW","BK4141","SNGX","BK4139","MNQmain","FUFU","BK4129","TQQQ","ABEO","SUUN","BK4204","BK4539","PERF","BK4173","ALCO","QLD","BK4023","TMC","ACU","BK4229","BETR","BK4082","PSQ","BK4168","ACXP","BK4085","SRTS","ABL","SJ","BK4563","ABLLL","BK4097","WISA","NQmain",".IXIC","THAR","DUOT","ASNS","BK4020","BK4108"],"gpt_icon":1},{"id":"2485275484","title":"Tharimmune Abandons Acquisition of Intract Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2485275484","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485275484?lang=en_us&edition=fundamental","pubTime":"2024-11-22 07:08","pubTimestamp":1732230480,"startTime":"0","endTime":"0","summary":"Tharimmune said it has terminated its non-binding letter of intent to combine with Intract Pharma.The clinical-stage biotechnology company said in September that it had signed an exclusive letter of intent to acquire all outstanding shares of the privately held Intract in exchange for newly issued Tharimmune stock.According to a securities filing on Thursday, Tharimmune has provided Intract with notice that the letter of intent has been nixed.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THAR","BK4139"],"gpt_icon":0},{"id":"2485426004","title":"BRIEF-Tharimmune Inc Increases Board Size To Six","url":"https://stock-news.laohu8.com/highlight/detail?id=2485426004","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485426004?lang=en_us&edition=fundamental","pubTime":"2024-11-22 05:56","pubTimestamp":1732226218,"startTime":"0","endTime":"0","summary":"BRIEF-Tharimmune Inc Increases Board Size To SixNov 21 (Reuters) - Tharimmune Inc THAR.O:THARIMMUNE INC - INCREASES BOARD SIZE TO SIXSource text: [https://tinyurl.com/4exxmans]Further company coverage: THAR.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nFWN3MS0LP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THAR","BK4139"],"gpt_icon":0},{"id":"2485426092","title":"Tharimmune Inc - Increases Board Size to Six","url":"https://stock-news.laohu8.com/highlight/detail?id=2485426092","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485426092?lang=en_us&edition=fundamental","pubTime":"2024-11-22 05:55","pubTimestamp":1732226135,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nFWN3MS0LP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["THAR","BK4139"],"gpt_icon":0},{"id":"2484678203","title":"Tharimmune presents clinical data on TH104 for chronic pruritus","url":"https://stock-news.laohu8.com/highlight/detail?id=2484678203","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484678203?lang=en_us&edition=fundamental","pubTime":"2024-11-18 22:00","pubTimestamp":1731938431,"startTime":"0","endTime":"0","summary":"Tharimmune (THAR) presented new TH104 clinical data at the American Association for the Study of Liver Disease The Liver Meeting 2024, underway in ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tharimmune-presents-clinical-data-on-th104-for-chronic-pruritus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tharimmune-presents-clinical-data-on-th104-for-chronic-pruritus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","THAR"],"gpt_icon":0},{"id":"2484622121","title":"Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2484622121","media":"ACCESSWIRE","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484622121?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:00","pubTimestamp":1731934800,"startTime":"0","endTime":"0","summary":"Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected treatment-emergent adverse events. Phase 2 preliminary data for chronic pruritus in primary biliary cholangitis expected in 2025. BRIDGEWATER, NJ / ACCESSWIRE / November 18, 2024 / Tharimmune, Inc.  , a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, presented new TH104 clinical data at the American Association for the Study of Liver Disease  The Liver Meeting 2024, underway in San Diego from November 15-19. The Phase 1 trial was a single-dose, single-center, open-label, randomized study of TH104 transmucosal buccal film conducted in two cohorts of patients with chronic liver disease , with the primary outcome of safety and tolerability.This study screened 19 patients and 12 were enrolled with two types of CLD categorized as Child-Pugh A  and Child-Pugh B . The Child-Pugh score is a system for assessing ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UZTpE1I7SAphgBk547xy2A--~B/aD00Mzk7dz00MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/f703bc8c191cae054ccd693dc3d4af55","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UZTpE1I7SAphgBk547xy2A--~B/aD00Mzk7dz00MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/f703bc8c191cae054ccd693dc3d4af55"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tharimmune-presents-positive-clinical-data-130000509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PK","BK4181","THAR","BK4218","BK4022","PBC","R","BK4232"],"gpt_icon":0},{"id":"2483885388","title":"Tharimmune granted patent for delivery of molecularly targeted therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2483885388","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483885388?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:57","pubTimestamp":1731506234,"startTime":"0","endTime":"0","summary":"Tharimmune (THAR) announced that the European Patent Office intends to grant the Company a patent covering biodegradable polymeric nanoparticles cr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tharimmune-granted-patent-for-delivery-of-molecularly-targeted-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tharimmune-granted-patent-for-delivery-of-molecularly-targeted-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","THAR"],"gpt_icon":0},{"id":"2483007516","title":"Tharimmune: Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2483007516","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483007516?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:12","pubTimestamp":1731503538,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nFWN3MK1HZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["THAR","BK4139"],"gpt_icon":0},{"id":"2483007512","title":"Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2483007512","media":"ACCESSWIRE","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483007512?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:00","pubTimestamp":1731502800,"startTime":"0","endTime":"0","summary":"BRIDGEWATER, NJ / ACCESSWIRE / November 13, 2024 / Tharimmune, Inc.  , a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that the European Patent Office intends to grant the Company a patent covering biodegradable polymeric nanoparticles created for carrying therapeutic and targeting agents. With particular utility in cancer therapies, this innovative platform is designed to enhance the delivery of therapeutic antibodies and peptides, which are often limited by enzymatic degradation and poor systemic circulation.Tharimmune, Inc. is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology and inflammation. The lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis , a rare autoimmune liver disease with no known cure. The expanded pipeline includes TH023, an oral TNF-alpha inhibitor, offering a new ap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tharimmune-granted-european-patent-delivery-130000865.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["THAR","PBC","LENZ","BK4139"],"gpt_icon":1},{"id":"2480586212","title":"Tharimmune Announces Upcoming Conference Presentations","url":"https://stock-news.laohu8.com/highlight/detail?id=2480586212","media":"ACCESSWIRE","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480586212?lang=en_us&edition=fundamental","pubTime":"2024-11-04 22:00","pubTimestamp":1730728800,"startTime":"0","endTime":"0","summary":"BRIDGEWATER, NJ / ACCESSWIRE / November 4, 2024 / Tharimmune, Inc.  , a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces that management will be participating in two upcoming conferences.Randy Milby, Chief Executive Officer, will attend the 2024 Spartan Capital Investor Conference being held on November 4, 2024 in New York and hold one-on-one meetings. Interested investors can register to attend the conference and schedule meetings here.Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the timing and design of Tharimmune's future Phase 2 trial, Tharimmune's strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking stateme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tharimmune-announces-upcoming-conference-presentations-140000877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PBC","BK4139","THAR"],"gpt_icon":1},{"id":"2479733406","title":"Tharimmune Shares Climb on Positive Feedback From EMA on Potential Pruritus Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2479733406","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479733406?lang=en_us&edition=fundamental","pubTime":"2024-10-30 23:06","pubTimestamp":1730300791,"startTime":"0","endTime":"0","summary":"Tharimmune  shares climbed by more than 130% in recent Wednesday trading after the company said it received \"positive feedback\" from the European Medicines Agency about TH104, its candidate to treat moderate-to-severe pruritus in primary biliary cholangitis, or PBC.The feedback came in a Scientific Advice meeting, the company said, where the agency provided guidance on a planned phase 2 trial to advance TH104.The agency noted that there was no need to conduct additional animal studies and considered human exposure adequate to move forward, the company added.Tharimmune said it plans to start a phase 2 multiple-ascending dose trial in the coming months to evaluate the safety and tolerability of TH104, and expects topline data in 2025.Price: 4.46, Change: +2.44, Percent Change: +120.79","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","THAR"],"gpt_icon":0},{"id":"2479078738","title":"Dow Surges Over 150 Points; Alphabet Posts Upbeat Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2479078738","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479078738?lang=en_us&edition=fundamental","pubTime":"2024-10-30 23:04","pubTimestamp":1730300659,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/10/41627875/dow-surges-over-150-points-alphabet-posts-upbeat-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APDN","IE00BJTD4N35.SGD","QLD","LU0082616367.USD","GOOG","IE00BFXG0V08.USD","LU0203201768.USD","LU0348723411.USD","IE00BFSS8Q28.SGD","BK4091","IE00BKDWB100.SGD","BK4547","PSQ","IE0004091025.USD","LU0170899867.USD","LU0154236417.USD","LU0289941410.SGD","LU0234570918.USD","VEV","BK4588","PCOM","LU0061474960.USD","BK4533","LU0719512351.SGD","LU0128525689.USD","NQmain","IE0004086264.USD","LU0053666078.USD","IE00B1BXHZ80.USD","LU0289960550.SGD",".IXIC","THAR","IE00BJTD4V19.USD","IE00BFSS7M15.SGD","BK4538","MNQmain","GOOGL","TQQQ","BK4527","LU0234572021.USD","LU0187121727.USD","SQQQ","LU0203202063.USD","QID","ENSC","BK4573","SVMH","BK4077"],"gpt_icon":1},{"id":"2479620266","title":"Tharimmune receives regulatory feedback from EMA for TH104 program","url":"https://stock-news.laohu8.com/highlight/detail?id=2479620266","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479620266?lang=en_us&edition=fundamental","pubTime":"2024-10-30 20:46","pubTimestamp":1730292375,"startTime":"0","endTime":"0","summary":"Tharimmune (THAR) received feedback from a Scientific Advice meeting with the European Medicines Agency that included guidance on a planned Phase 2...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tharimmune-receives-regulatory-feedback-from-ema-for-th104-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tharimmune-receives-regulatory-feedback-from-ema-for-th104-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["THAR","BK4139"],"gpt_icon":0},{"id":"2479201848","title":"Tharimmune - Receives Positive Regulatory Feedback From Ema for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2479201848","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479201848?lang=en_us&edition=fundamental","pubTime":"2024-10-30 20:16","pubTimestamp":1730290574,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241030:nFWN3M61K0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["THAR","BK4139"],"gpt_icon":0},{"id":"2479201507","title":"Tharimmune Inc - Expects Topline Data in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2479201507","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479201507?lang=en_us&edition=fundamental","pubTime":"2024-10-30 20:16","pubTimestamp":1730290574,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241030:nFWN3M61K0:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","THAR"],"gpt_icon":0},{"id":"2479201503","title":"Tharimmune - Plans to Initiate Phase 2 Multiple-Ascending Dose Trial in Coming Months to Assess Safety and Tolerability of TH104","url":"https://stock-news.laohu8.com/highlight/detail?id=2479201503","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479201503?lang=en_us&edition=fundamental","pubTime":"2024-10-30 20:16","pubTimestamp":1730290574,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241030:nFWN3M61K0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["THAR","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":43,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/THAR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-25","symbol":"THAR","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742875200000,"reportTimeType":"post","actualEps":-2.02},{"market":"US","date":"2024-08-09","symbol":"THAR","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723176000000,"reportTimeType":"","actualEps":-2.42},{"market":"US","date":"2024-05-28","symbol":"THAR","defaultRemindTime":1716903000000,"type":"split","dateTimestamp":1716868800000,"forFactor":15,"toFactor":1,"ratio":15},{"market":"US","date":"2024-05-09","symbol":"THAR","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"pre","actualEps":-0.19},{"date":"2024-02-23","symbol":"THAR","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1708678800000,"name":null,"time":"Pre-Market","dateTimestamp":1708664400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"THAR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"THAR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1737777600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/THAR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"THAR","date":"2025-04-21","current":-0.195341,"percent":0.850704,"low":-0.588474,"twenty":-0.432349,"median":-0.309492,"eighty":-0.246337,"high":-0.078899,"avg":-0.323035,"sd":0.115965,"marketCap":2382680},"quantilePoints":[{"date":"2023-09-29","current":-0.382876,"twenty":-0.507054,"median":-0.396691,"eighty":-0.388402,"marketCap":3414917},{"date":"2023-10-05","current":-0.371034,"twenty":-0.396296,"median":-0.39077,"eighty":-0.38406,"marketCap":3309301},{"date":"2023-10-10","current":-0.365113,"twenty":-0.395507,"median":-0.388797,"eighty":-0.373639,"marketCap":3256493},{"date":"2023-10-19","current":-0.400638,"twenty":-0.396296,"median":-0.385837,"eighty":-0.371823,"marketCap":3573340},{"date":"2023-10-27","current":-0.354061,"twenty":-0.395901,"median":-0.382876,"eighty":-0.367481,"marketCap":3157918},{"date":"2023-11-02","current":-0.314984,"twenty":-0.394717,"median":-0.375178,"eighty":-0.354061,"marketCap":2809385},{"date":"2023-11-10","current":-0.37416,"twenty":-0.396691,"median":-0.374981,"eighty":-0.345575,"marketCap":3222178},{"date":"2023-11-17","current":-0.366027,"twenty":-0.394717,"median":-0.374571,"eighty":-0.354061,"marketCap":3152131},{"date":"2023-11-24","current":-0.23385,"twenty":-0.395112,"median":-0.373042,"eighty":-0.340009,"marketCap":2013859},{"date":"2023-12-01","current":-0.246337,"twenty":-0.391559,"median":-0.36684,"eighty":-0.303758,"marketCap":2121398},{"date":"2023-12-08","current":-0.177715,"twenty":-0.389586,"median":-0.365113,"eighty":-0.2671,"marketCap":1530437},{"date":"2023-12-15","current":-0.142524,"twenty":-0.386603,"median":-0.352622,"eighty":-0.21331,"marketCap":1227380},{"date":"2023-12-22","current":-0.155427,"twenty":-0.384688,"median":-0.345575,"eighty":-0.188612,"marketCap":1338501},{"date":"2023-12-29","current":-0.146629,"twenty":-0.383782,"median":-0.317747,"eighty":-0.176783,"marketCap":1262737},{"date":"2024-01-05","current":-0.146659,"twenty":-0.38276,"median":-0.312306,"eighty":-0.157175,"marketCap":1262989},{"date":"2024-01-12","current":-0.139005,"twenty":-0.38091,"median":-0.292008,"eighty":-0.148917,"marketCap":1197074},{"date":"2024-01-19","current":-0.114078,"twenty":-0.375376,"median":-0.280942,"eighty":-0.146629,"marketCap":982409},{"date":"2024-01-26","current":-0.133403,"twenty":-0.374981,"median":-0.23385,"eighty":-0.14311,"marketCap":1148838},{"date":"2024-02-02","current":-0.127861,"twenty":-0.37416,"median":-0.20534,"eighty":-0.138301,"marketCap":1101106},{"date":"2024-02-09","current":-0.111585,"twenty":-0.371924,"median":-0.18314,"eighty":-0.129796,"marketCap":960942},{"date":"2024-02-16","current":-0.114019,"twenty":-0.371034,"median":-0.158301,"eighty":-0.127861,"marketCap":981904},{"date":"2024-02-23","current":-0.111145,"twenty":-0.367679,"median":-0.155427,"eighty":-0.121656,"marketCap":957154},{"date":"2024-03-01","current":-0.48475,"twenty":-0.37506,"median":-0.166843,"eighty":-0.12223,"marketCap":4517427},{"date":"2024-03-08","current":-0.465853,"twenty":-0.385872,"median":-0.188565,"eighty":-0.123227,"marketCap":4341332},{"date":"2024-03-15","current":-0.464846,"twenty":-0.39748,"median":-0.211982,"eighty":-0.126981,"marketCap":4331940},{"date":"2024-03-22","current":-0.557437,"twenty":-0.450736,"median":-0.23385,"eighty":-0.128799,"marketCap":5194806},{"date":"2024-03-28","current":-0.547624,"twenty":-0.468827,"median":-0.280942,"eighty":-0.129034,"marketCap":5103356},{"date":"2024-04-05","current":-0.579242,"twenty":-0.47694,"median":-0.299351,"eighty":-0.129034,"marketCap":5398007},{"date":"2024-04-12","current":-0.522329,"twenty":-0.488151,"median":-0.314984,"eighty":-0.129491,"marketCap":4867635},{"date":"2024-04-19","current":-0.477811,"twenty":-0.486603,"median":-0.348379,"eighty":-0.13196,"marketCap":4452767},{"date":"2024-04-26","current":-0.45669,"twenty":-0.485414,"median":-0.359587,"eighty":-0.135532,"marketCap":4255940},{"date":"2024-05-03","current":-0.477432,"twenty":-0.482784,"median":-0.366433,"eighty":-0.137304,"marketCap":4449231},{"date":"2024-05-10","current":-0.518662,"twenty":-0.485414,"median":-0.371924,"eighty":-0.137996,"marketCap":4833456},{"date":"2024-05-17","current":-0.488448,"twenty":-0.487514,"median":-0.375178,"eighty":-0.138723,"marketCap":4340799},{"date":"2024-05-24","current":-0.434206,"twenty":-0.489085,"median":-0.382876,"eighty":-0.14006,"marketCap":3858750},{"date":"2024-05-31","current":-0.396974,"twenty":-0.487825,"median":-0.388797,"eighty":-0.141468,"marketCap":3527876},{"date":"2024-06-07","current":-0.451939,"twenty":-0.486699,"median":-0.395704,"eighty":-0.142758,"marketCap":4016347},{"date":"2024-06-14","current":-0.295417,"twenty":-0.486079,"median":-0.392744,"eighty":-0.143233,"marketCap":2625343},{"date":"2024-06-21","current":-0.276843,"twenty":-0.48475,"median":-0.386969,"eighty":-0.143726,"marketCap":2460277},{"date":"2024-06-28","current":-0.285687,"twenty":-0.484266,"median":-0.384008,"eighty":-0.144206,"marketCap":2538880},{"date":"2024-07-05","current":-0.293648,"twenty":-0.483128,"median":-0.378835,"eighty":-0.145162,"marketCap":2609622},{"date":"2024-07-12","current":-0.336103,"twenty":-0.481172,"median":-0.37416,"eighty":-0.146207,"marketCap":2986917},{"date":"2024-07-15","current":-0.339198,"twenty":-0.48087,"median":-0.373042,"eighty":-0.146313,"marketCap":3014428},{"date":"2024-08-02","current":-0.39802,"twenty":-0.480567,"median":-0.37416,"eighty":-0.146418,"marketCap":3537173},{"date":"2024-08-09","current":-0.357356,"twenty":-0.479583,"median":-0.371479,"eighty":-0.146647,"marketCap":3175790},{"date":"2024-08-16","current":-0.388311,"twenty":-0.47931,"median":-0.367704,"eighty":-0.147503,"marketCap":3446280},{"date":"2024-08-23","current":-0.383133,"twenty":-0.478979,"median":-0.3683,"eighty":-0.148084,"marketCap":3400329},{"date":"2024-08-30","current":-0.3621,"twenty":-0.478193,"median":-0.368895,"eighty":-0.150559,"marketCap":3213656},{"date":"2024-09-06","current":-0.374966,"twenty":-0.47771,"median":-0.368895,"eighty":-0.152319,"marketCap":3327842},{"date":"2024-09-13","current":-0.387016,"twenty":-0.477508,"median":-0.371479,"eighty":-0.153668,"marketCap":3434792},{"date":"2024-09-20","current":-0.387573,"twenty":-0.477179,"median":-0.37416,"eighty":-0.156013,"marketCap":3439732},{"date":"2024-09-27","current":-0.318415,"twenty":-0.476049,"median":-0.370611,"eighty":-0.157456,"marketCap":2825949},{"date":"2024-10-04","current":-0.288644,"twenty":-0.474874,"median":-0.368895,"eighty":-0.165134,"marketCap":2561734},{"date":"2024-10-11","current":-0.263637,"twenty":-0.474587,"median":-0.367652,"eighty":-0.176316,"marketCap":2339794},{"date":"2024-10-18","current":-0.304177,"twenty":-0.472752,"median":-0.367031,"eighty":-0.182055,"marketCap":2699586},{"date":"2024-10-25","current":-0.259599,"twenty":-0.469988,"median":-0.36557,"eighty":-0.188659,"marketCap":2303953},{"date":"2024-10-31","current":-0.443968,"twenty":-0.46923,"median":-0.363606,"eighty":-0.192108,"marketCap":3940246},{"date":"2024-11-08","current":-0.314532,"twenty":-0.469028,"median":-0.3621,"eighty":-0.207997,"marketCap":2791486},{"date":"2024-11-15","current":-0.305403,"twenty":-0.46859,"median":-0.361023,"eighty":-0.220423,"marketCap":3313862},{"date":"2024-11-22","current":-0.357444,"twenty":-0.468401,"median":-0.359587,"eighty":-0.228864,"marketCap":3878556},{"date":"2024-11-29","current":-0.28486,"twenty":-0.468199,"median":-0.357833,"eighty":-0.23385,"marketCap":3090956},{"date":"2024-12-06","current":-0.278012,"twenty":-0.466808,"median":-0.355708,"eighty":-0.23385,"marketCap":3016655},{"date":"2024-12-13","current":-0.298555,"twenty":-0.465853,"median":-0.352068,"eighty":-0.239263,"marketCap":3239560},{"date":"2024-12-20","current":-0.287599,"twenty":-0.465417,"median":-0.349391,"eighty":-0.246337,"marketCap":3120677},{"date":"2024-12-27","current":-0.294447,"twenty":-0.465417,"median":-0.343978,"eighty":-0.247606,"marketCap":3194979},{"date":"2025-01-03","current":-0.280751,"twenty":-0.465265,"median":-0.340267,"eighty":-0.248902,"marketCap":3046375},{"date":"2025-01-10","current":-0.297186,"twenty":-0.465036,"median":-0.335817,"eighty":-0.250096,"marketCap":3224700},{"date":"2025-01-17","current":-0.273904,"twenty":-0.46288,"median":-0.332711,"eighty":-0.251506,"marketCap":2972074},{"date":"2025-01-24","current":-0.295816,"twenty":-0.459788,"median":-0.324576,"eighty":-0.253179,"marketCap":3209839},{"date":"2025-01-31","current":-0.271165,"twenty":-0.458942,"median":-0.322298,"eighty":-0.256285,"marketCap":2942353},{"date":"2025-02-07","current":-0.367119,"twenty":-0.457712,"median":-0.324576,"eighty":-0.25649,"marketCap":3983531},{"date":"2025-02-14","current":-0.338605,"twenty":-0.457135,"median":-0.332752,"eighty":-0.257766,"marketCap":3674130},{"date":"2025-02-21","current":-0.332011,"twenty":-0.45669,"median":-0.334163,"eighty":-0.259599,"marketCap":3602581},{"date":"2025-02-28","current":-0.258409,"twenty":-0.45669,"median":-0.332711,"eighty":-0.258409,"marketCap":2803941},{"date":"2025-03-07","current":-0.279794,"twenty":-0.452773,"median":-0.327411,"eighty":-0.258409,"marketCap":3035992},{"date":"2025-03-14","current":-0.258409,"twenty":-0.451939,"median":-0.323592,"eighty":-0.257308,"marketCap":2803941},{"date":"2025-03-21","current":-0.27623,"twenty":-0.447209,"median":-0.318081,"eighty":-0.256285,"marketCap":2997317},{"date":"2025-03-28","current":-0.235121,"twenty":-0.446876,"median":-0.316359,"eighty":-0.256285,"marketCap":2867904},{"date":"2025-04-04","current":-0.216104,"twenty":-0.443968,"median":-0.314758,"eighty":-0.253062,"marketCap":2635941},{"date":"2025-04-11","current":-0.183256,"twenty":-0.434206,"median":-0.310649,"eighty":-0.250909,"marketCap":2235278},{"date":"2025-04-17","current":-0.190171,"twenty":-0.43272,"median":-0.309629,"eighty":-0.247606,"marketCap":2319628},{"date":"2025-04-21","current":-0.195341,"twenty":-0.432349,"median":-0.309492,"eighty":-0.246337,"marketCap":2382680}],"updateTime":1745321361421}}}